Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

Plain-language summary

This study evaluates the use of the growth hormone drug Somatropin in a patient carrying a dominant-negative mutation in the GHR gene. It involves the specific patient who has this GHR mutation leading to high GHBP levels. The study is in Phase 2 and is currently active but not recruiting new participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Active, not recruiting

Sponsor

Children's National Research Institute

Intervention

Somatropin

Start date

8/26/2022

Estimated completion

9/1/2028

Countries

United States

Related genes

Locations

• Washington D.C., United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Be the specific subject with the a specific mutation in GHR leading to high GHBP.

Exclusion Criteria:

There are no exclusion criteria for this study.